ADT-007

• Description:

  ADT-007 is a potent and orally active pan-RAS inhibitor with strong anticancer effects. ADT-007 binds RAS in a nucleotide-free conformation to block GTP activation. ADT-007 potently and selectively inhibits the growth of cancer cells with mutated or hyper-activated wild-type RAS isozymes[1].

• UNSPSC:

  12352005

• Target:

  Ras

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; MAPK/ERK Pathway

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/adt-007.html

• Purity:

  99.97

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  O=C(NCC1=CC=CO1)CC2=C(C)/C(C3=CC=C(F)C=C32)=C/C4=CC(OC)=C(C(OC)=C4)O

• Molecular Formula:

  C26H24FNO5

• Molecular Weight:

  449.47

• References & Citations:

  [1]Jeremy B Foote, et al. A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer. bioRxiv[Preprint]. 2024 Jan 24:2023.05.17.541233.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1945941-09-2]